I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019, that the first patient has...
Read moreTarget Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US and China while...
Read moreTerns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...
Read moreCASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...
Read moreJiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with...
Read moreHansoh Pharma completed a highly successful Hong Kong IPO, pricing last week at the top end of its range, and then following up with a 37% rise in its first trading session today. The IPO raised $1 billion for the company at a valuation of $10.7...
Read moreReistone, a one-year-old Shanghai-Beijing-Boston biopharma, has dosed the first patient in global Phase II trial of its JAK1 inhibitor in patients with Ulcerative Colitis and Crohn’s disease. The JAK1 candidate was developed by Jiangsu...
Read moreMORE Health, Inc., a global healthcare company, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, that gives patients from across the world...
Read moreTessa Therapeutics, a Singapore company, will form a $120 million JV with China-Singapore Guangzhou Knowledge City (CSGKC) to develop Tessa’s oncology cell therapies in China. The companies will fund the JV in two stages, with Tessa...
Read moreTerns Pharma, a Silicon Valley-Shanghai company, started a US Phase I clinical trial of TERN-101 to treat non-alcoholic steatohepatitis (NASH). TERN-101 is a farnesoid X receptor (FXR) agonist. One year ago, Terns in-licensed three drug...
Read moreVarian Medical (NYSE: VAR) today announced the Proton Clinical Research Center of the Shandong Cancer Hospital, is the first center in Asia Pacific to join the FlashForward™ Consortium. The Consortium now includes 15 institutions and is focused...
Read morePAREXEL, a leader in the development of innovative new therapies to improve the world’s health, today announced a strategic partnership with Clariness, a leading global patient recruitment company, to further accelerate clinical trial recruitment...
Read more
